ZLAB — Zai Lab Limited American Depositary Shares stock price and chart

Data provided bySource: Twelve Data

ZLAB

$24.60-5.53%

as of close, Nov 13, 2026

☾ AH $24.60 -5.53%

Zai Lab Limited American Depositary SharesStock · HealthcareEmerging Markets · 0.02% of VWO

PeersONCSPYQQQNVDAAAPLMSFT

Share this page

Head-to-head:Compare with ONC or any ticker →

Technical analysis2

Overlay lines0

Addendum charts0

Volume4.5M

EEEEEEEEEEEEEEEEEEEEEE

2018201820192020202120222023202420252026

0.020.040.060.080.0100.0120.0140.0160.0180.0200.005.0M10.0M15.0M$24.60

2026-11-13

Price$24.60

MA20$23.66

MA50$20.87

Vol4.5M

Data provided bySource: Twelve Data

What would $1,000 invested in ZLAB be worth today? →

ZLAB returns: By year · By month · By week · Trailing

Key stats#

Data provided bySource: Twelve Data

Price data

Price: $24.60
YTD price return: +39.46%
YTD total return: +39.46%
Market cap: 2.8B2017-09 26.1M2026-11 2.8B+10511.8% over the window
Enterprise value: 2.5B
Shares outstanding: 112.4M2016-12 965.7K2026-09 112.4M+11542.4% over the window
52W low: $15.96
52W high: $29.02
From 52W high: -15.23%
From 52W low: +54.14%
52W range: 66%$15.96–$29.02

Volume

Rel volume: 1.07×
30D volume: 1.1M
30D $ vol: 27.7M

Fundamentals

Sales (ttm): 441.7M2018-12 129K2026-09 441.7M+342324.0% over the window
Sales/share: $3.932018-12 $0.022026-09 $3.93+17672.9% over the window
EPS (ttm): -$1.782020-12 -$3.502026-09 -$1.78-49.1% over the window
FCF (ttm): -163.3M2016-12 -34.4M2026-09 -163.3M+375.1% over the window
FCF/share: -$1.452016-12 -$35.602026-09 -$1.45-95.9% over the window
Book value/share: $5.012016-12 -$53.382026-09 $5.01-109.4% over the window
Net margin: -44.91%2018-12 -107810.1%2026-09 -44.9%-100.0% over the window
ROE: -35.22%2017-12 -21.4%2026-09 -35.2%+64.4% over the window
ROA: -19.38%2016-12 -42.2%2026-09 -19.4%-54.1% over the window
Current ratio: 2.042016-12 16.252026-09 2.04-87.5% over the window

Growth (CAGR, ttm) · 10Y

Sales: +0.02%2025-09-30 → 2026-09-30441.6M → 441.7M (+0.0% total)+18.79%2023-09-30 → 2026-09-30263.5M → 441.7M (+67.6% total)+30.84%2021-09-30 → 2026-09-30115.2M → 441.7M (+283.3% total)n/a
Shares: +1.67%2025-09-30 → 2026-09-30110.6M → 112.4M (+1.7% total)+5.08%2023-09-30 → 2026-09-3096.9M → 112.4M (+16.0% total)+63.84%2021-09-30 → 2026-09-309.5M → 112.4M (+1080.1% total)+62.92%2016-12-31 → 2026-09-30965.7K → 112.4M (+11542.4% total)

Per-share growth (CAGR, ttm) · 10Y

Sales/share: -1.62%2025-09-30 → 2026-09-30$3.99 → $3.93 (-1.6% total)+13.05%2023-09-30 → 2026-09-30$2.72 → $3.93 (+44.5% total)-20.14%2021-09-30 → 2026-09-30$12.10 → $3.93 (-67.5% total)n/a
Book value/share: -27.11%2025-09-30 → 2026-09-30$6.87 → $5.01 (-27.1% total)-18.01%2023-09-30 → 2026-09-30$9.09 → $5.01 (-44.9% total)-50.39%2021-09-30 → 2026-09-30$166.67 → $5.01 (-97.0% total)n/a
Price: +13.22%2025-11-13 → 2026-11-13$21.73 → $24.60 (+13.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-3.10%2023-11-13 → 2026-11-13$27.04 → $24.60 (-9.0% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-21.99%2021-11-12 → 2026-11-13$85.17 → $24.60 (-71.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/a
Total return: +13.22%2025-11-13 → 2026-11-13$21.73 → $24.60 (+13.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-3.10%2023-11-13 → 2026-11-13$27.04 → $24.60 (-9.0% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-21.99%2021-11-12 → 2026-11-13$85.17 → $24.60 (-71.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: -13.8×2017-09 -0.702026-11 -13.95+1906.6% over the window
Fwd P/E: -13.3×
P/S (ttm)Market cap ÷ TTM revenue.: 6.3×2018-12 1050.412026-11 6.26-99.4% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 4.9×2017-09 -0.512026-11 4.91-1071.2% over the window
EV/Sales (ttm): 5.6×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: -5.91%2017-12 -202.3%2026-09 -5.5%-97.3% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-09-30) ÷ shares_at(2025-09-30) = 1 − 112.4M ÷ 110.6M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -1.67%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-1.67%) + dividends paid over that year ($0) ÷ market_cap_at(2025-09-30) ($3.7B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -1.67%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($2.8B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2017-12 0.0%2026-09 0.0%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($2.8B). Same caveat as the cash buyback yield.: 0.00%2017-12 0.0%2026-09 0.0%

Vs own 10Y history

P/S: 20th
P/B: 97th

Bar = where today’s multiple sits in ZLAB’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-13#

Data provided bySource: Twelve Data

-5.53%

-3.45%

+6.49%

-5.49%

YTD

+39.46%

+13.21%

-71.12%

-5.53%

-3.45%

+6.49%

-5.49%

YTD

+39.46%

+13.21%

-71.12%

Fundamentals#

Revenue

5Y CAGR +56.5%5Y CAGR +56.5%YoY −6.8%

$441.7M TTM$108.2M Q3 '26

FY18FY19FY20FY21FY22FY23FY24FY25TTM

Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m10Y n/mYoY n/m

−$278.3M TTM−$63M Q3 '26

FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m5Y n/mYoY n/m

−$1.78 TTM−$0.40 Q3 '26

FY20FY21FY22FY23FY24FY25TTM

Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y n/m5Y n/mYoY n/m

−$163.3M TTM−$58.8M Q3 '26

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow −$159.2M, capex −$4.1M

Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow −$57.9M, capex −$947K

Shares (diluted)

5Y +41.0%5Y +41.0%YoY +1.9%

111.3M TTM112.3M Q3 '26

FY20FY21FY22FY23FY24FY25TTM

Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y n/m10Y n/mYoY n/m

−$198.4M TTM−$46.1M Q3 '26

FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Full ZLAB financials →

About Zai Lab ADR#

Data provided bySource: Twelve Data

Zai Lab Limited ADR is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for serious diseases with unmet medical needs. Zai Lab Limited ADR's current portfolio centers on oncology, immunology, infectious diseases, and neuroscience, with marketed products that help address conditions such as certain cancers, autoimmune disorders, and bacterial infections. The company works through a combination of in-house research, licensing, and global collaboration to bring medicines from development into commercial use. Its product lineup includes therapies such as Zejula, Optune, Qinlock, and Nuzyra, reflecting a business model that combines innovation with ongoing commercialization across specialty healthcare markets. Zai Lab Limited ADR plays a role in the biopharmaceutical sector by supplying treatments for complex conditions where therapeutic options remain limited, serving patients, healthcare providers, and partners across China and other international markets.

Pudong, China·1,784 employees·Biotechnology·zailaboratory.com·As of Oct 28, 2026

ETFs holding ZLAB#

5 of the 193 ETFs ChartRow carries live hold ZLAB. Their positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Jul 26).

Fund	Name	Filed weight
IBB	iShares Biotechnology ETF	0.1%
VWO	Vanguard FTSE Emerging Markets ETF	0.0%
VEU	Vanguard FTSE All-World ex-US ETF	0.0%
VXUS	Vanguard Total International Stock ETF	0.0%
VT	Vanguard Total World Stock ETF	0.0%

Data provided bySource: Twelve Data

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+23.75%	+1.14%
JNJ	Johnson & Johnson	+14.94%	+0.79%
ABBV	AbbVie Inc.	+7.53%	+0.20%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+7.86%	+0.58%
MRK	Merck & Co. Inc.	+4.07%	+0.55%
NVS	Novartis AG	+12.70%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+5.61%	+0.11%
AMGN	Amgen Inc.	+12.80%	-0.30%

Head-to-head:Compare with ONC or any ticker →

ZLAB — Zai Lab Limited American Depositary Shares price, chart and key statistics

Key stats#

Price data

Volume

Fundamentals

Growth (CAGR, ttm) · 10Y

Per-share growth (CAGR, ttm) · 10Y

Valuation

Vs own 10Y history

Performance · price returntotal return · as of 2026-11-13#

Fundamentals#

Revenue

Operating income

EPS (diluted)

Free cash flow

Shares (diluted)

Net income

About Zai Lab ADR#

ETFs holding ZLAB#

Related Healthcare#